Shares of Airsculpt Technologies (NASDAQ: AIRS) plummeted 30.41% in pre-market trading on Friday following the release of disappointing third-quarter results and reduced full-year guidance. The aesthetic surgery company's financial performance fell short of analyst expectations across multiple key metrics, raising concerns about its near-term growth prospects.

For the third quarter, Airsculpt reported revenue of $35 million, missing analyst estimates of $39.5 million by 11.46%. This figure represents a significant 17.8% decrease from the $42.5 million reported in the same quarter last year. The company's adjusted EBITDA came in at $3 million, falling short of the expected $3.81 million. Airsculpt also posted a wider net loss of $9.5 million, compared to a $6 million loss in the prior-year period.

In light of the weak results, Airsculpt has lowered its full-year 2025 revenue outlook to approximately $153 million, down from its previous guidance range of $160 million to $170 million. CEO Yogi Jashnani attributed the lower-than-anticipated revenue to timing issues rather than a change in the overall trajectory of the business. However, investors appear skeptical, as reflected in the sharp pre-market sell-off. The significant drop in share price underscores the market's concerns about Airsculpt's ability to meet future growth expectations in the competitive aesthetic surgery industry.